Abbott Labs (NYSE:ABT) and Mylan (NASDAQ:MYL) gave investors reason to cheer today. Mylan bought up Abbott's established pharmaceuticals portfolio in non-emerging, ex-U.S. markets for $5.3 billion in an all-stock deal.
Was it a good idea for Mylan shareholders?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.
Everyone already knows about this deal
That's not a bad thing, but multibagger investments usually crop up when an investor recognizes true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson owns shares of Abbott Laboratories. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.